Global Inflammatory Bowel Disease (IBD) Diagnostic Market Size and Share
| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 4.03 Billion |
| Market Size (2030) | USD 4.85 Billion |
| CAGR (2025 - 2030) | 3.78% |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Global Inflammatory Bowel Disease (IBD) Diagnostic Market Analysis by Mordor Intelligence
The Global Inflammatory Bowel Disease Diagnostic Market size is estimated at USD 4.03 billion in 2025, and is expected to reach USD 4.85 billion by 2030, at a CAGR of 3.78% during the forecast period (2025-2030).
The COVID pandemic and statewide lockdown have had a major impact on patients with inflammatory bowel disease (IBD), including delayed diagnosis and problems getting healthcare. According to the study titled "Reduction in Inflammatory Bowel Disease Healthcare During the Coronavirus Disease 2019 Pandemic: A Nationwide Retrospective Cohort Study" published in the Gastroenterology in February 2021, IBD diagnoses dropped by 6.5% during the COVID-19 pandemic, with a maximum drop of 46.3%. The number of additional infection-related complications has increased along with COVID-19 prevalence. A report by the Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE-IBD) database in January 2022, indicated that among patients with IBD, adverse COVID-19 outcomes were related to age and other co-morbidities. Thus, the decline in the IBD diagnosis during COVID-19 significantly hampered the market growth.
The market is driven by the rise in the prevalence of IBD, the growing need for early diagnosis of IBD, and product launches by the key market players. According to a report by the Centers for Disease Control and Prevention (CDC) published in April 2021, on World IBD Day (May 19), about 7 million around the world suffer from IBD. The report also stated that the rate of prevalence of the disease has significantly increased during the last two decades. Thus, the growing prevalence of the IBD is anticipated to drive the demand for its diagnosis thereby boosting the market. Additionally, according to the study titled "Temporal trends in the epidemiology of inflammatory bowel diseases in the public healthcare system in Brazil: A large population-based study" by Aderson O.M.C. Damiao, published in June 2022, in Brazil, the prevalence of ulcerative colitis and crohn's disease rose from 30.0 per 100,000 in 2012 to 100.1 per 100,000 in 2020 and 15.7 to 56.5 per 100,000 in 2012 to 12.6 to 33.7 per 100,000 in 2020 respectively. Thus, the growing prevalence of IBD diseases such as crohn's disease and ulcerative colitis is anticipated to drive the demand for its diagnosis thereby boosting segment growth.
Additionally, the market growth is supported by several strategies used by the major market players, including product launches, mergers, and acquisitions. For instance, in November 2021, Medtronic plc received the United States Food and Drug Administration (FDA) clearance for its PillCam Small Bowel 3 system for remote endoscopy procedures.
The market is anticipated to grow as a result of the rising demand for IBD diagnoses. However, it is anticipated that the lack of public awareness and strict regulations for entry may impede the market's expansion.
Global Inflammatory Bowel Disease (IBD) Diagnostic Market Trends and Insights
Endoscopy Segment is Expected to Account for the Highest Market Share
An endoscopy is a medical treatment that allows doctors to view the body. An endoscope is used in the endoscopy technique to inspect the interior of a hollow organ or cavity of the body. Endoscopes, unlike many other medical imaging procedures, are put directly into the organ.
According to the study titled " Capsule Endoscopy in Inflammatory Bowel Disease: When? To Whom?" published in December 2021, capsule endoscopy (CE) has proven to be a helpful diagnostic technique for IBD, particularly Crohn's disease (CD) capsule endoscopy (CE) produces high-resolution endoluminal pictures of the small bowel. As a result, the advantages of endoscopy over other techniques support the segment's growth during the forecast period.
In addition, key initiatives taken by the market players like mergers, acquisitions, and partnerships strengthen their product portfolio in the region, thereby driving the market. For instance, in November 2021, RoundTable Healthcare Partners' portfolio company, Healthcare Components Group ("HCG") acquired Endoscopy Development Company ("EDC") which will bring all endoscopy components under one shop in both the optical and flexible categories.
Thus, all factors mentioned above boost the segment growth over the forecast period.
North America Dominates the Market and Expected to do the same in the Forecast Period
North America currently dominates the market for inflammatory bowel disease and is expected to continue its stronghold for a few more years. In the North American region, the United States holds the largest market share. One of the reasons for market growth is that in the United States, a rising prevalence of IBD diseases and growing demand for early diagnosis as well as product launches by the key market players.
According to the study published in the National Library of Medicine by Christopher McDowell; in May 2022, for ulcerative colitis and Crohn's diseases, the incidence of inflammatory bowel disease (IBD) in North America has ranged from 2.2 to 19.2 cases per 100,000 people in a year and 3.1 to 20.2 cases per 200,000 people in a year respectively. Adult ulcerative colitis and Crohn's disease prevalence in the United States were 238 per 100,000 people and 201 per 100,000 people, respectively. Therefore, it is anticipated that the rising prevalence of IBD diseases in the nation will increase demand for its diagnosis and thus propel market expansion.
According to the study titled "Validation of the newly Food and Drug Administration-approved Buhlmann fCal Turbo assay for measurement of fecal calprotectin in a pediatric population" published in the Practical Laboratory Medicine in November 2020, the study concluded that the fCal Turbo assay has been helpful as a quick screening method for IBD disease monitoring and differential diagnosis.
Therefore, it is anticipated that the market will grow due to the rising prevalence of IBD diseases and the increase in research studies evaluating various IBD diagnostic techniques.
Competitive Landscape
The Inflammatory Bowel Disease (IBD) diagnostics market is fragmented and competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market DiaSorin S.p.A, Quidel Corporation, and American Laboratory Products Company (ALPCO), Certest Biotec SL, and others.
Global Inflammatory Bowel Disease (IBD) Diagnostic Industry Leaders
-
DiaSorin S.p.A
-
BUHLMANN Laboratories AG
-
Quidel Corporation
-
Certest Biotec SL.
-
American Laboratory Products Company (ALPCO)
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- In June 2022, Sentinel Diagnostics has launched the launch of the SENTiFIT 800 Analyzer, a fully automated and high throughput system for Fecal Immunochemical tests.
- In March 2022, Stanford Children's Health has opened a new Center for Pediatric Inflammatory Bowel Disease (IBD) and Celiac Disease to expand access to care and research for children.
Global Inflammatory Bowel Disease (IBD) Diagnostic Market Report Scope
As per the scope of this report, inflammatory bowel disease (IBD) is characterized by chronic inflammation of the gastrointestinal (GI) tract. The two classifications of IBD are Crohn's disease and ulcerative colitis. Prolonged inflammation can cause damage to the GI tract. The inflammatory Bowel Disease (IBD) Diagnostic Market is segmented by Diagnostics (Blood Tests, Fecal Tests, Endoscopy, Biopsy and Others), Disease Type (Ulcerative Colitis, Crohn's Disease), End User (Hospitals, Diagnostic Laboratories, Others End User), Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The report offers values (in USD) for the above segments.
| Blood Test |
| Fecal Test |
| Endoscopy |
| Biopsy |
| Others |
| Ulcerative Colitis |
| Crohns Disease |
| Hospitals |
| Diagnostic Laboratories |
| Others End User |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
| By Test Type | Blood Test | |
| Fecal Test | ||
| Endoscopy | ||
| Biopsy | ||
| Others | ||
| By Diseases Type | Ulcerative Colitis | |
| Crohns Disease | ||
| By End User | Hospitals | |
| Diagnostic Laboratories | ||
| Others End User | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Europe | Germany | |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Asia-Pacific | China | |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Middle East and Africa | GCC | |
| South Africa | ||
| Rest of Middle East and Africa | ||
| South America | Brazil | |
| Argentina | ||
| Rest of South America | ||
Key Questions Answered in the Report
How big is the Global Inflammatory Bowel Disease Diagnostic Market?
The Global Inflammatory Bowel Disease Diagnostic Market size is expected to reach USD 4.03 billion in 2025 and grow at a CAGR of 3.78% to reach USD 4.85 billion by 2030.
What is the current Global Inflammatory Bowel Disease Diagnostic Market size?
In 2025, the Global Inflammatory Bowel Disease Diagnostic Market size is expected to reach USD 4.03 billion.
Who are the key players in Global Inflammatory Bowel Disease Diagnostic Market?
DiaSorin S.p.A, BUHLMANN Laboratories AG, Quidel Corporation, Certest Biotec SL. and American Laboratory Products Company (ALPCO) are the major companies operating in the Global Inflammatory Bowel Disease Diagnostic Market.
Which is the fastest growing region in Global Inflammatory Bowel Disease Diagnostic Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Global Inflammatory Bowel Disease Diagnostic Market?
In 2025, the North America accounts for the largest market share in Global Inflammatory Bowel Disease Diagnostic Market.
What years does this Global Inflammatory Bowel Disease Diagnostic Market cover, and what was the market size in 2024?
In 2024, the Global Inflammatory Bowel Disease Diagnostic Market size was estimated at USD 3.88 billion. The report covers the Global Inflammatory Bowel Disease Diagnostic Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Inflammatory Bowel Disease Diagnostic Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Page last updated on:
Global Inflammatory Bowel Disease (IBD) Diagnostic Market Report
Statistics for the 2025 Global Inflammatory Bowel Disease (IBD) Diagnostic market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Inflammatory Bowel Disease (IBD) Diagnostic analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
